

Volume - 10

No. 7

July-2017

ISSN: 0972-8988

EISSN: 2231-0916



NAAS Rating : 5.71

Indexed in ESCI-Thomson Reuters, PubMed,
PubMed Central, DOAJ, Scopus, CABI, CAS etc.

Veterinary World

Open access and peer reviewed journal



Editorial office

Veterinary World,
Star, Gulshan Park,
NH-8A, Chandrapur Road,
Wankaner - 363621,
Dist. Morbi, Gujarat, India
Website: www.veterinaryworld.org
E-mail: editorveterinaryworld@gmail.com

Veterinary World

Editorial Office: Veterinary World, Star, Gulshan Park, NH-8A, Chandrapur Road, Wankaner - 363621, Dist. Morbi, Gujarat, India

[ISSN: 0972-8988, EISSN: 2231-0916, www.veterinaryworld.org]

Editor-in-Chief

Anjum V. Sherasiya - Ex-Veterinary Officer, Department of Animal Husbandry, Gujarat State, India

Associate Editors

Shambhunath Choudhary - Department of Biomedical & Diagnostic Sciences, College of Veterinary Medicine, The University of Tennessee, 2407 River Drive, Room A 201, Knoxville, TN 37996, U.S.A.

Suresh H. Basagoudanavar - FMD Vaccine Research Laboratory, IVRI, Bangalore, Bangalore- 560024, Karnataka, India

Editorial board

R. G. Jani - Coordinator Wildlife Health, Western Region Centre, Indo-US Project, Department of Veterinary Medicine, Veterinary College, Anand - 388001, Gujarat, India

G. N. Gongal - Technical Officer, WHO South-East Asia Regional Office, New Delhi - 110002, India

Ranganath Mamidi - Dr. Julian E. Steizer's Lab, Department of Physiology & Biophysics, Medical School, Case Western Reserve University, Cleveland, OH - 44106, U.S.A.

Md. Tanvir Rahman - Department of Microbiology and Hygiene, Faculty of Veterinary Science, Bangladesh Agricultural University, Mymensingh-2202, Bangladesh

Deepnala Agarwal - Cancer Prevention Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, U.S.A.

Foud Kasim Mohammad - Professor, Department of Pharmacology & Toxicology, Vice President for Administrative & Financial Affairs, University of Mosul, P.O. Box 11136, Mosul, Iraq

Abdel-Baset Nasr Sayed Ahmed - Professor and Head, Department of Animal Nutrition and Clinical Nutrition, Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt

Nicole Borel - Department of Pathology, Vetsuisse Faculty, University of Zurich, CH-8057 Zurich, Switzerland

B. A. Lubisi - Virology, MED Programme, ARC - Onderstepoort Veterinary Institute, No. 100 Old Soutpan Road, Onderstepoort, Tshwane, 0110, South Africa

Kumar Venkitanarayan - Associate Professor, Graduate Programs Chair, Honors and Pre-Vet Programs Advisor, Department of Animal Science, University of Connecticut, Storrs, CT 06269, U.S.A.

Kemin Xu - Department of Veterinary Medicine, University of Maryland, College Park College Park, MD, 20742, U.S.A.

Vassilis Papatsiros - Faculty of Veterinary Medicine, Department of Medicine (Porcine Medicine), University of Thessaly, Thessaly, Greece

Mathias Devreese - Laboratory of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Ghent University, Belgium

Sumeet Sharma - Edmonton North Animal Hospital, Edmonton, Alberta, T5X 3Y7, Canada

K. P. Singh - School of Medicine and Dentistry, University of Rochester, Department of Environmental Medicine, Room: 4-6820, 601 Elmwood Avenue, Box-EHSC, Rochester, New York-14620, U.S.A.

Raj Mohan Raja Muthiah - Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, U.S.A.

Ashok K. Chockalingam - Division of Applied Regulatory Science, U.S. Food and Drug Administration, 10903, New Hampshire Avenue, Silver Spring, Maryland 20993, U.S.A.

Ashutosh Wadhwa - Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Mail Stop G33, Atlanta, GA 30333, U.S.A.

Luiz Otavio Pereira Carvalho - Laboratory of Immunomodulation and Protozoology, Oswaldo Cruz Institute, Ministry of Health (Brazil), Pavilhão "108" - Sala: 09, Av. Brasil, 4365 - Manguinhos, Rio de Janeiro - RJ, CEP: 21040-360, Brazil.

Editorial office contact person: Anjum V. Sherasiya, email: editorveterinaryworld@gmail.com

Ratings of Veterinary World: NAAS - National Academy of Agricultural Sciences - 5.71, Scimago Journal Rank - 0.265, Citiscore - 0.49, SNIP - Source Normalized Impact per Paper - 0.600

Indexing and abstracting

Academic Journals Database, AGORA, AGRICOLA, AGRIS, CABI, CAS, DOAJ, EBSCO, ESCI - Thomson Reuters, Gale, Google Scholar, HINARI, Index Scholar, Indian Animal Science Abstracts, Indian Science Abstracts, JournalSeek, Open J-gate, ProQuest, PubMed, PubMed Central, SCOPUS, TEEAL

Publisher: Veterinary World

Veterinary World is an open access journal, each issue available free of cost at www.veterinaryworld.org.

We accept online submission only. For more information regarding submission and publication charges, please visit www.veterinaryworld.org

Printed and Published by Dr. Anjum V. Sherasiya on behalf of Veterinary World. Printed and Published at Star, Gulshan Park, N.H. 8A, Chandrapur Road, Wankaner-363621, Dist. Morbi, Gujarat, India.
Editor-in-Chief: Dr. Anjum V. Sherasiya

Veterinary World

ISSN: 0972-8988, EISSN: 2231-0916, www.veterinaryworld.org

Volume-10

No.7

July-2017

The articles in Veterinary World are open access articles licensed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Research (Published online: 01-07-2017)

1. Screening method for *Staphylococcus aureus* identification in subclinical bovine mastitis from dairy farms
Natapol Pumipuntu, Suphang Kulpeanprasit, Sirijan Santajit, Witawat Tunyong, Thida Kong-ngoeng, Woranich Hinthong and Nitaya Indrawattana
Veterinary World, 10(7): 721-726

Research (Published online: 02-07-2017)

2. Performance of broiler chicken fed multicarbohydrases supplemented low energy diet
Kumar Govil, Sunil Nayak, R. P. S. Baghel, A. K. Patil, C. D. Malapure and Dinesh Thakur
Veterinary World, 10(7): 727-731

Research (Published online: 03-07-2017)

3. Cuticular surface damage of *Ascaridia galli* adult worms treated with *Veitchia merrillii* betel nuts extract in vitro
Ummu Balqis, Muhammad Hambal, Rinidar, Farida Athaillah, Ismail, Azhar, Henni Vanda and Darmawi
Veterinary World, 10(7): 732-737

Research (Published online: 04-07-2017)

4. Detection and characterization of pathogenic *Pseudomonas aeruginosa* from bovine subclinical mastitis in West Bengal, India
S. Banerjee, K. Batabyal, S. N. Joardar, D. P. Isore, S. Dey, I. Samanta, T. K. Samanta and S. Murmu
Veterinary World, 10(7): 738-742

Research (Published online: 05-07-2017)

5. Anti-diarrhea activity of the aqueous root bark extract of *Byrsocarpus coccineus* on castor oil-induced diarrhea in Wistar rats
Sunday A. Ejeh, Patrick Onyeyili and Samson E. Abalaka
Veterinary World, 10(7): 743-747

Research (Published online: 06-07-2017)

6. Noninvasive assessment of gastrointestinal parasites infection in freeranging wild herbivores and adjoining livestock of Panna Tiger Reserve, Madhya Pradesh, India
Abhay Sengar, A. B. Shrivastav, K. P. Singh and Amol Rokde
Veterinary World, 10(7): 748-751

Research (Published online: 07-07-2017)

7. Repair of segmental radial defect with autologous bone marrow aspirate and hydroxyapatite in rabbit radius: A clinical and radiographic evaluation
Kalbaza Ahmed Yassine, Benchohra Mokhtar, Hemida Houari, Amara Karim, and Melizi Mohamed
Veterinary World, 10(7): 752-757

Research (Published online: 08-07-2017)

8. Evaluation of crude larval protein and recombinant somatic protein 26/23 (rHcp26/23) immunization against *Haemonchus contortus* in sheep
Omnia M. Kandil, Khaled A. Abdelrahman, Hatem A. Shalaby, Seham H. M. Hendawy, Nadia M. T. Abu El Ezz, Somia A. Nassar and James E. Miller
Veterinary World, 10(7): 758-763

Research (Published online: 10-07-2017)

9. Effects of commonly used chemical fertilizers on development of free-living stages of *Haemonchus contortus* in experimentally infected pasture
Tapas Kumar Roul, Mitra Rajan Panda, Bijayendranath Mohanty, Kautuk Kumar Sardar, Manaswini Dehuri, Ananta Hembram and Trilochan Mohapatra
Veterinary World, 10(7): 764-768

Research (Published online: 11-07-2017)

10. Serotyping, antibiotic susceptibility, and virulence genes screening of *Escherichia coli* isolates obtained from diarrheic buffalo calves in Egyptian farms

Ashraf S. Hakim, Shima T. Omara, Sohier M. Syame and Ehab A. Fouad
Veterinary World, 10(7): 769-773

Research (Published online: 13-07-2017)

11. Prevalence and antimicrobial resistance pattern of Shiga toxinogenic *Escherichia coli* in diarrheic buffalo calves

M. Srivani, Y. Narasimha Reddy, K. V. Subramanyam, M. Ramakoti Reddy and T. Srinivasa Rao
Veterinary World, 10(7): 774-778

Research (Published online: 15-07-2017)

12. Semen characteristics, extension, and cryopreservation of Rusa deer (*Rusa timorensis*)

Wan-Nor Fitri, Haron Wahid, Yusoff Rosnina, Faez Firdaus Abdullah Jesse, Zainal Abidin Aimi-Sarah, Mohd Lila Mohd-Azmi, Che' Amat Azlan, Muhammad Rashid Azrolharith, Innocent Damudu Peter and Falah Hasan Ali Baiee
Veterinary World, 10(7): 779-785

Research (Published online: 16-07-2017)

13. Alterations in lipid profile in neonatal calves affected by diarrhea

K. Bozukluhan, O. Merhan, H. I. Gokce, H. A. Deveci, G. Gokce, M. Ogun and S. Marasli
Veterinary World, 10(7): 786-789

Research (Published online: 19-07-2017)

14. Phenotypic approach artemisinin resistance in malaria rodent as in vivo model

Lilik Maslachah, Thomas V. Widiyatno, Lita Rakhma Yustinasari and Hani Plumeriastuti
Veterinary World, 10(7): 790-797

Research (Published online: 20-07-2017)

15. Identification of *Toxocara* spp. eggs in dog hair and associated risk factors

Tania O. Rojas, Camilo Romero, Rafael Heredia, Linda G. Bautista and Galia Sheinberg
Veterinary World, 10(7): 798-802

Research (Published online: 21-07-2017)

16. Antibiotic and heavy metal resistance of *Aeromonas hydrophila* and *Edwardsiella tarda* isolated from red hybrid tilapia (*Oreochromis* spp.) coinfecting with motile *aeromonas* septicemia and edwardsiellosis

S. W. Lee and W. Wendy
Veterinary World, 10(7): 803-807

Research (Published online: 23-07-2017)

17. Effects of herbal ointment containing the leaf extracts of Madeira vine (*Anredera cordifolia* (Ten.) Steenis) for burn wound healing process on albino rats

Wiwik Misaco Yuniarti and Bambang Sektiari Lukiswanto
Veterinary World, 10(7): 808-813

Research (Published online: 23-07-2017)

18. Characterization of *Salmonella Gallinarum* isolates from backyard poultry by polymerase chain reaction detection of invasion (*invA*) and *Salmonella* plasmid virulence (*spvC*) genes

Susmita Pal, Samir Dey, Kunal Batabyal, Abhiroop Banerjee, Siddhartha Narayan Joardar, Indranil Samanta and Devi Prasad Isore
Veterinary World, 10(7): 814-817

Research (Published online: 24-07-2017)

19. Baseline hematology and serum biochemistry results for Indian leopards (*Panthera pardus fusca*)

Arun Attur Shanmugam, Sanath Krishna Muliya, Ajay Deshmukh, Sujay Suresh, Anukul Nath, Pa Kalaignan, Manjunath Venkataravanappa and Lyju Jose
Veterinary World, 10(7): 818-824

Research (Published online: 28-07-2017)

20. Probiotic characterization of lactic acid bacteria isolated from swine intestine

K. Balasingham, C. Valli, L. Radhakrishnan and D. Balasuramanyam
Veterinary World, 10(7): 825-829

Research (Published online: 29-07-2017)

21. Serogrouping and antibiotic resistance of *Escherichia coli* isolated from broiler chicken with colibacillosis in center of Algeria

Zehor Halfaoui, Nabil Mohamed Menoueri and Lyes Mohamed Bendali
Veterinary World, 10(7): 830-835

Research (Published online: 31-07-2017)

22. Effect of paddy straw plus nonforage fiber sources based complete rations with different levels of neutral detergent fiber on hemato-biochemical and mineral profile of lactating dairy cows

Biju Chacko, K. M. Syam Mohan, K. Ally, K. Shyama, K. S. Anil and C. T. Sathian
Veterinary World, 10(7): 836-842

Phenotypic approach artemisinin resistance in malaria rodent as *in vivo* model

Lilik Maslachah¹, Thomas V. Widiyatno², Lita Rakhma Yustinasari³ and Hani Plumeriastuti⁴

1. Department of Basic Medicine, Veterinary Pharmacy Laboratory, Faculty of Veterinary Medicine, Airlangga University Surabaya, Indonesia; 2. Department of Pathology, Faculty of Veterinary Medicine, Airlangga University Surabaya, Indonesia; 3. Department of Veterinary Anatomy, Faculty of Veterinary Medicine, Airlangga University Surabaya, Indonesia; 4. Department of Veterinary Pathology, Faculty of Veterinary Medicine, Airlangga University Surabaya, Indonesia.

Corresponding author: Lilik Maslachah, e-mail: lilik.maslachah@yahoo.com

Co-authors: TVW: thvwidiyatno@gmail.com, LRY: lita.yustinasari@gmail.com, HP: plumeriastutihoney@gmail.com

Received: 14-01-2017, **Accepted:** 05-06-2017, **Published online:** 19-07-2017

doi: 10.14202/vetworld.2017.790-797 **How to cite this article:** Maslachah L, Widiyatno TV, Yustinasari LR, Plumeriastuti H (2017) Phenotypic approach artemisinin resistance in malaria rodent as *in vivo* model, *Veterinary World*, 10(7): 790-797.

Abstract

Aim: The aim of this study is to prove the development of artemisinin resistance phenotypically in malaria rodent as an *in vivo* resistance development model in humans.

Materials and Methods: *Plasmodium berghei* was infected intraperitoneally in mice, then artemisinin was given with "4-day-test" with effective dose (ED) 99% dose for 3 days which begins 48 h after infection (D2, D3, and D4). Parasite development was followed during 5th until 10th days of infection. After parasitemia >2% of red blood cell which contains parasites on 1 mice, that mice were used as donor to be passaged on the new 5 mice. After that, parasitemia was calculated. ED₅₀ and ED₉₀ were examined with parasite clearance time (PCT), recrudescence time (RT), and also morphology development examination of intraerythrocytic cycle of *P. berghei* with transmission electron microscope.

Results: Among the control group compare with the treatment group showed significant differences at $\alpha=0.05$ on 5th day (D5) until 10th day (D10). The control group of 4th passage (K4) with passage treatment group of 4th passage (P4) on the 10th days (D10) post infection showed no significant differences in the $\alpha=0.05$. The average percentage of inhibition growth was decreasing which is started from 5th to 10th day post infection in P1, P2, P3, and P4. On the development of *P. berghei* stage, which is given repeated artemisinin and repeated passage, there was a formation of dormant and also vacuoles in *Plasmodium* that exposed to the drug.

Conclusion: Exposure to artemisinin with repeated passages in mice increased the value of ED₅₀ and ED₉₀, decreased the PCT and RT and also changes in morphology dormant and vacuole formation.

Keywords: artemisinin, parasite clearance time, phenotypic, *Plasmodium berghei*, recrudescence time, resistance.

Introduction

Malaria is still a public health problem in more than 90 countries. A rapid increasing incidence of morbidity and mortality of malaria is caused by increasing parasite resistance to antimalarial drugs. A new drug for malaria treatment which is used until right now is artemisinin and its derivatives; this drug has the effect of working faster than other antimalarial drugs because they have more complex mechanisms of action. However, there have been indicated that the *Plasmodium* parasite has been resistant to this drug [1]. Clinical results already shown in two patients infected with *Plasmodium falciparum* that was resistant to artesunate in Cambodia [2]. Results of the research show a decrease in efficacy against malaria falciparum

to the combination of artesunate-mefloquine in Cambodia [3].

Results of *in vitro* studies on *P. falciparum* which is exposed with repeated artemisinin as antimalarial drug showed an increase of 50% inhibitory concentration (IC₅₀), phenotypic changes dormant, and faster growth after *Plasmodium* viable from a dormant form. Besides, the exposure to artemisinin also causes mutations in genes *pfatpase6* [4]. The presence of parasite pressure on the use of drugs with subcurative doses will lead to the development of new parasite that can survive on the drug. The results of this research become an emergency because it could be developed resistance in human being and lead to be one of health problems in the world because there is no substitute for a new drug artemisinin. Malaria treatment failure using antimalarial drug artemisinin and its derivatives appears to be an era of untreatable malaria.

In vivo experimental studies using rodent malaria used to support the translation of laboratory studies into clinical studies, because the spectrum of malaria in humans is not yet clearly understood how the mechanism of the pathogenesis. So that, this study could be used to explain the mechanisms of resistance

Copyright: Maslachah, et al. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

to artemisinin *in vivo* using mice as an animal model that infected with *Plasmodium berghei*. Resistance of malaria and developed resistance to antimalarial drugs need to do research to develop effective control strategies for malaria. However, this research is really difficult to conduct in endemic areas because of the many confounding factors such as infection multiple clones of infective mosquito bites that spreading. This research also impossible to do in humans because of ethical reason [5]. This study used rodent malaria as a model of resistance *in vivo* in humans by doing exposure to *P. berghei* with artemisinin on effective dose 99% (ED₉₉: 200 mg/kg weight of mice) through repeated passage in mice. Exposure of artemisinin as antimalarial drug with repeated passage *in vivo* in mice can be used as a basic to predict and anticipate the spread of artemisinin antimalarial drug resistance in practical use in the clinic.

Materials and Methods

Ethical approval

This study was conducted after getting approval with certificate number no. 464 KE from the Animal Ethics Committees of Faculty of Veterinary Medicine, Airlangga University Surabaya Indonesia.

Parasites, host, and drugs that used in the study

A parasite which is used to infect mice is *P. berghei* ANKA strain. Mice which are used are male Albino Swiss strain, the weight is 20-30 g, and the aged is 2.5 months. Artemisinin which is used pro analysis from Sigma Chemical Co.

Infection dose of *P. berghei* in mice

Mice is infected with red blood cells (RBCs) containing parasites 1×10^5 *P. berghei* in 0.2 ml intraperitoneally. To determine the infection has occurred in mice, microscopic examination of erythrocytes of mice was done every day with thin blood smears that taken from tail vein of mice and stained with Giemsa 20% [6].

Selection of artemisinin antimalarial drug resistance *in vivo* in mice

Exposure to artemisinin antimalarial drug in the treatment group: After inoculation of RBCs containing parasites 1×10^5 *P. berghei* in 0.2 ml on 5 mices (D0) and then given artemisinin antimalarial drug with "4-day-test" with ED₉₉ dose (200 mg/kg weight of mice) was given for 3 days started at 48 h after infection (D2). Parasitemia was monitored and calculated at 120 h after infection. After parasitemia >2% of RBCs containing parasites, they are used as donor and was passaged on new 6 mice. After 48 h post infection, the mice were exposed to artemisinin antimalarial drug with the same ED₉₉ dose for 3 consecutive days 4 times passages. Control group: After inoculation of RBCs containing parasites 1×10^5 *P. berghei* in 0.2 ml at 6 mice (D0) was given no medication, parasitemia monitored and calculated at 48 h after infection. After parasitemia >2% of RBCs

containing parasites, they are used as donor and was passaged on the new 5 mice, and the passages were repeated on mice 4 times. The development of parasite was followed until 10th day of infection in all treatments [7,8].

Parasitemia calculation

Calculation of parasitemia in mice for each exposure to artemisinin and every passage in mice conducted after 120 h (D5) post infection. Thin smear of blood vessels from tail vein of mice is made, then fixed with methanol, stained with Giemsa 20% for 20 min, then washed with water and dried. After that, the percentage of parasitemia of *P. berghei* was calculated by counting the number of infected erythrocytes per 1000 erythrocytes under a light microscope with 1000x magnification [9,10].

Measurement of 50% and 90% ED level (ED₅₀ and ED₉₀)

Measurement of ED₅₀ and ED₉₀ level for each exposure to the artemisinin antimalarial drug in mice was counted every passage 120 h (D5) post infection using the formula: $(A-B)/A \times 100$

Where, A is the average parasitemia in control group and B is parasitemia in treatment group. Determination ED₅₀ and ED₉₀ is calculated using a linear regression program [11].

Examination of parasite clearance time (PCT) and recrudescence time (RT) of *P. berghei*

Examination of PCT and RT *P. berghei* was done by checking the growth of the parasite 48 h after completion of treatment for 3 days or 120 h (D5) post infection which is showed by the absence of parasites in the thin blood smear of mice that taken from a tail vein and stained with Giemsa 20% for 20 min and examined using a light microscope with 1000x magnification and followed every day to see the development until 10th day post infection until discovered a parasite >5% that can grow back (RT) [12].

Morphological stadium observation of *P. berghei* development

Morphological stage observation of the intraerythrocytic cycle development of *P. berghei* ring, trophozoites and schizonts in the control group and the treatment of exposure to artemisinin-dose ED₉₉ with repeated passages in mice was conducted every 48 h on 5th, 6th, 8th, and 10th day post infection by counting the number of development dormant, ring, trophozoites and schizonts stage in thin blood smears that stained with 20% Giemsa for 20 min and examined using light microscope with 1000x magnification [13,14].

Ultrastructural morphology observation with a transmission electron microscope (TEM)

RBC washed with sodium cacodylate pH 7.4, 500 mL and fixed with 5% glutaraldehyde containing cacodylate buffer pH 7.4 and 3% sucrose for 24 h (stored at a temperature of 4°C). Rinsed with sodium cacodylate 0.1 M pH 7.4 for 15 min and fixation is

using osmium tetroxide 2% and potassium ferricyanide $K_3Fe(CN)_6$ in 0.1 M cacodylate buffer, then dehydrated with gradual concentration of ethanol. Then, tissue is immersed back with a solution of pure Spurr and entered in a vacuum incubator 70°C overnight. This preparation will result tissue block with hard consistency. Tissue is cut with diamond knife with 40-55 nm thick and attached to the grid which has been coated with formvar 5% in chloroform and consists of 200 mesh. Results of pieces were stained with uranyl acetate, followed with triple lead then examined using a JEOL 1010 TEM. Morphology of *P. berghei* parasites in erythrocytes that have been exposed to artemisinin was observed and compared with negative control of *P. berghei* (without drug exposure) [15].

Statistical analysis

The data on parasitemia percentage and growth inhibition of *P. berghei* were processed with two-way ANOVA with the level of significance set at 5% to determine differences in treatment. The data ED_{50} and ED_{90} level, PCT, and RT of *P. berghei* were analyzed with linear regression using SPSS 17.0 and morphology *P. berghei* developmental stage was analyzed with description

Results

Results of parasitemia percentage and growth inhibition of *P. berghei* in the repeated passage on the D5-D10 post infection after being given artemisinin for 3 days in the 2nd day post infection

Percentage of parasitemia of *P. berghei*, which is repeated passage in D5-D10 after being given artemisinin for 3 days in D2 post infection showed that among the control group (K1 to K4) and the treatment group (P1 to P4) on the repeated passage (1st passage to 4th passage) showed significant differences in the $\alpha=0.05$ on day 5 (D5) up to day 10 (D10) post infection except in the 4th passage control group (K4) with 4th passage treatment group (P4) on 10th day (D10) post infection showed no significant differences in the $\alpha=0.05$. That results are tested with the average difference test and two tail t-test. The results of this study also showed that *P. berghei* infection with repeated passage (P1, P2, P3, and P4) in mice that were given artemisinin repeatedly showed a decrease of % growth inhibition (Figure-1).

Measurements ED_{50} and ED_{90} level *P. berghei* that repeated passages on the D5-D10 after being given artemisinin for 3 days in D2 post infection

Linear regression test is known that ED_{50} and ED_{90} *P. berghei* in P1 ED_{50} on 9.3th days and ED_{90} on 5.7th days with the regression equation. $Y=152.41-10.96 X$. On P2 ED_{50} on 8.3th days and ED_{90} on 5.6th with the regression equation $Y=172.41-14.62 X$. On P3 ED_{50} on 7.9th days and ED_{90} on 5.6th days with the regression equation $Y=187.78-17.37 X$. On P4 ED_{50} on 7.5th days and ED_{90} on 5.4th days with the regression equation $Y=192.13-18.8 X$ (Figure-2).




Figure-1: Graphic of *Plasmodium berghei* parasitemia percentage which is repeated passage on D5- D10 after treated artemisinin for 3 days in D2 post infection. K1: Control once passage untreated, K2: Control twice passage untreated, K3: Control 3 times passage untreated, K4: Control 4 times passage untreated P1: Once treated and once passage, P2: Twice treated and twice passage, P3: 3 times treated and 3 times passage, P4: 4 times treated and 4 times passage.

PCT and RT *P. berghei* that repeated passages on the D5-D10 after being given artemisinin for 3 days in D2 post infection

Artemisinin that given for 3 days in D2 post infection, then after reaching parasitemia 2% was passage to the new mice and given repeated artemisinin with the same dose up to 4 times passage shows PCT after 3 days of artemisinin treatment with dose 200 mg/kg body weight of mice on D5% parasitemia in P1 is approximately 0.362, P2 0.120, P3 0.140, and P4 0.140. RT *P. berghei* is counted after parasitemia reach 5% after treatment for 3 days. The results of RT on P1 parasitemia reach 5% after 7.7 days with the equation of regression is $Y=-11.22+2.13 X$. P2 parasitemia reach 5% after 6.61 days with the equation of regression is $Y=-21.55+4.02 X$. P3 parasitemia reach 5% after 6.9 days with the equation of regression is $Y=-18.63+3.43 X$. P4 parasitemia reach 5% after 6.5 days with the equation of regression is $Y=-27.56+5.03 X$ (Figure-3).

Morphology *P. berghei* that passage repeatedly after having been given artemisinin for 3 days in D2 post infection

Morphology of *P. berghei* with TEM control and treatment groups (Figure-4).

Morphology of *P. berghei* developmental stages that passage repeatedly on D5-D10 after having been given artemisinin for 3 days in D2 post infection

The description of developmental stages of *P. berghei* which passage repeatedly on D5-D10 after having been given artemisinin for 3 days in D2 post infection showed that in the control group which only infected with *P. berghei* did not show any formation dormant in all of the control group that passaged repeatedly while in the treatment group that infected with *P. berghei* and treated artemisinin for 3 days in D2 post infection, there was a formation of dormant (Figure-5).




Figure-2: Graphic of linear regression of 50% and 90% effective dose level *Plasmodium berghei* that repeated passages on the D5-D10 after treated artemisinin for 3 days in D2 post infection. P1: Once treated and once passage, P2: Twice treated and twice passage, P3: 3 times treated and 3 times passage, P4: 4 times treated and 4 times passage.




Figure-3: Parasite clearance time and recrudescence time *Plasmodium berghei* that repeated passages on the D5-D10 after treated artemisinin for 3 days in D2 post infection. P1: Once treated and once passage, P2: Twice treated and twice passage, P3: 3 times treated and 3 times passage, P4: 4 times treated and 4 times passage.




Figure-4: Morphology of *Plasmodium berghei* with transmission electron microscope on control and treatment artemisinin groups. N: Nucleus, V: Vacuole, DV: Digestive vacuole. (a) Control untreated, (b) once treated and once passage, (c) twice treated and twice passage, (d) 3 times treated and three times passage, (e) 4 times treated and 4 times passage.

Discussion

Results of parasitemia percentage and inhibition growth of *P. berghei* that passaged repeatedly on D5-D10 post infection after being given artemisinin for 3 days in D2 post infection

The percentage of parasitemia in *P. berghei* that passaged repeatedly on the D5-D10 after having been given artemisinin for 3 days in D2 post infection show decreasing percentage of parasitemia when compared with the control group. Artemisinin can decrease the parasite significantly within 24-48 h after treatment and more potent than other antimalarials drugs, but artemisinin and its derivatives have $t_{1/2}$ elimination in 1 h so that is unable to eliminate the parasite after 3 days of treatment. Therefore, artemisinin should be combined with other drugs such as amodiaquin, piperiaquin, etc., to extend the working time of the medicine (duration of action) so that the recrudescence after administration of artemisinin can be avoided [16].

Repeated passage of *P. berghei* up to 4 times after have been given artemisinin showed an increased percentage of parasitemia in the treatment group which is showed by significant differences between the treatment groups that passage 1 times, 2 times, 3 times, and 4 times. This suggests that the parasite is viable after drug exposure more than once showed development toward resistant by the image of an extension of PCT and increased of speed recrudescence [17]. This is shown by the results % inhibition growth that decreases continually and increases the growth rate in the treatment group that passaged repeatedly.

The results of this research on the 4th passage of control group 4 (K4) with 4th passage of treatment group (P4) on 10th day (D10) post infection showed no significant difference with the control group which were not given artemisinin at $\alpha=0.05$. This suggests that the growth rate of the treatment group which was given repeated artemisinin up to 4 times with the same dose for each passage is not able to inhibit parasite growth with the same dose. The results of *in vivo* studies using mice as a model to be infected with *P. berghei* is consistent with *in vitro* research that is using *P. falciparum*, and the result showed an increasing value of IC_{50} for each repeated exposure to artemisinin which means that inhibit 50% of parasite requires a higher dose than the dose of artemisinin earlier [18].

Results of measurements ED_{50} and ED_{90} level *P. berghei* that passages repeatedly on the D5-D10 after being given artemisinin for 3 days in D2 post infection

Results of linear regression test are known that ED level ED_{50} and ED_{90} *P. berghei* after repeated exposure of artemisinin in the repeated passage and given artemisinin on the same dose for each passage showed an increasing of ED_{50} and ED_{90} which is to inhibit parasite growth in the same time. The results indicate that the ED of artemisinin to inhibit *P. berghei* growth is increasing by shortening of the required time for the parasite to grow back so that the parasites require higher doses to be able to inhibit its growth in the same time.

The results are consistent with research with the selection of resistant *P. berghei* to pyronaridine by repeated passage 20 times for 6 months. The results showed ED_{50} and ED_{90} increased from 40 to 66 time [11]. The results are consistent with research in *P. falciparum* F32 Tanzania strain that exposed to artemisinin for 3 years with low concentrations 0.01 μM , and then, concentrations are increased up to 10 μM for 100 exposure times. The results after selection of F32-ART strain showed that F32-ART with higher artemisinin exposure (35 and 70 μM) for 96 h, only on F32-ART strain that has been selected will able to survive [19]. Other studies from the results of research in *P. falciparum* GC06 and CH3-61 strains before and after selection with artemisinin with increased concentrations of each of 0-20 and 0-100 nM, after the parasite is viable, its is showed an increasing IC_{50} values on the strains after selection with artemisinin which is the first GC06 strain has IC_{50} value from 3.1 ± 0.1 changed to 12.5 ± 1.6 nM and the first CH3-61 strains have IC_{50} values from 28.8 ± 1.3 changed to 58.3 ± 4.5 nM [16].

Research conducted by Tucker *et al.* [20] also showed that the parasite that has been resistant required greater concentrations of the drug to inhibit parasite growth compared to its stem. IC_{50} has increased in the resistant parasite compared with parasitic stem on artemisinin, which is described




Figure-5: Morphology of *Plasmodium berghei* developmental stages which repeated passage on D5-D10 after treated artemisinin for 3 days in D2 post infection. K1: Control once passage untreated, K2: Control twice passage untreated, K3: Control 3 times passage untreated, K4: Control 4 times passage untreated P1: Once treated and once passage, P2: Twice treated and twice passage, P3: 3 times treated and 3 times passage, P4: 4 times treated and 4 times passage.

as follows: Stem of W2 strain has a value of IC_{50} 1.3 ± 0.71 ng/ml, resistant W2QSH200x2 strain have IC_{50} values 4.2 ± 2.2 ng/ml, stem of D6 strain has IC_{50}

value 0.92 ± 0.10 ng/ml, resistant D6QSH2400x5 strain have IC_{50} value 8.8 ± 1.0 ng/ml and the stem of TM91c235 strain showed IC_{50} values 2.2 ± 1.8 ng/ml,

and resistant TM91c235AL280x2 strain have IC₅₀ value 8.7±5.4 ng/ml. This means that resistant parasites have an ability to withstand in higher drug induction.

Increasing the value of IC₅₀ become 2-5 times also apply during three parasite strains that have been tolerant to acid artelinic, changes in the value of IC₅₀ were also followed with an increasing in the number of copies, the expression of mRNA, and protein expression of *pfmdr1* genes [21].

Examination of PCT and RT *P. berghei* that passaged repeatedly on the D5-D10 after being given artemisinin for 3 days in D2 post infection

The provision of artemisinin for 3 days in D2 post infection, then after reaching parasitemia 2% was passages to the new mice and given artemisinin repeatedly with the same dose 4 times passage shows PCT after 3 days of artemisinin treatment dose of 200 mg/kg body weight of mice on D5 showed an extension time of PCT and accelerate RT. It was shown from the results that the PCT in P1 ranging from 0.362, P2 0.120, P3 0.140, and P4 0.140 with dormant morphology. RT *P. berghei* is calculated after parasitemia reach 5% after receiving treatment for 3 days. The results of RT on P1 after 7.7 days, P2 after 6.61 days, P3 after 6.9 days, and P4 after 6.5 days; the results are consistent with research conducted by Teuscher *et al.* [22] that treatment with dormant form of artesunate from ring stadium is expected 0.001-1313 to grow back. Recovery from dormant parasite is a time to reach 5% parasitemia in the form of dormant. This is also found in the mice. From the results of research conducted by La Crue *et al.* [12] shows that the form of dormant ring began recrudescence about 7-9 days. RT is consistent with the results of research which the ranges are 7.7 days post infection and the time that required is shorter after 2nd, 3rd and 4th times of passage.

The overview morphology of dormant in *P. falciparum* which exposed to artemisinin antimalarial drug is a defence mechanism for the parasite to be able to survive from the exposure to artemisinin antimalarial drug. Parasites will be able to grow normally after the drug pressure is removed. In this dormant period, the parasite can survive in a few days by slowing down the process of metabolism to limit the effects of the drugs because there is no DNA synthesis in this situation [19].

This results are consistent with research conducted by Tucker *et al.* [20] on *P. falciparum* D6 stem strain with *P. falciparum* in strain that has been resistant D6QSH2400x5 showed normal morphology after exposure to artemisinin antimalaria, require faster time to grow back to normal and the ratio of the morphology of normal parasites two times higher in the parasite which has been resistant when compared with the stem parasitic strains. This shows that the strain of parasite that has been already resistant to artemisinin have an ability to produce more dormant parasites and can be faster to get out from dormant period (viable)

so that the parasites are already resistant to artemisinin have the speed of recovery is higher than the stem strain which are not resistant so it will accelerate its recrudescences.

Result of observations of morphology *P. berghei* that passage repeatedly after having been given artemisinin for 3 days in D 2 post infection

The description of developmental stages of *P. berghei* which passage repeatedly on D5-D10 after having been given artemisinin for 3 days in D2 post infection showed that in the control group, which only infected with *P. berghei* did not show any formation dormant in all of the control group that passaged repeatedly while in the treatment group that infected with *P. berghei* and given artemisinin for 3 days in D2 post infection, there were formations of dormant. The ability of the parasite in this dormant period as a resistance mechanism that leads to recrudescences of parasites and extension of PCTs.

The mechanism of artemisinin induces the formation of dormant is still unclear. However, it is believed that the existence of dormant stage is associated with cell cycle regulation such as cyclin-dependent kinase and cyclins. This dormant overview is also reported by Teuscher *et al.* [23] and Witkowski *et al.* [19]. Decreasing in metabolic activity on the stage of the ring as a prerequisite of the ability of resistant parasite to be a form of dormant on the artemisinin drug administration, so that the phenomenon can be used to explain the resistance to artemisinin is an increasing of parasites in the form of dormant (quiescence) from the ring in exposure to artemisinin antimalarial drug. Therefore, killing the resistant parasite required greater concentration of artemisinin antimalarial drug. If the concentration of the drug is same, the parasite is still able to survive and breed back with a faster time.

Ultrastructure by TEM on the ring stage that treated for 24 h with artemisinin showed a loss of substance of the membrane so that the crystal hemozoin is located in the cytoplasm of the parasite, and there was a formation of vacuoles. The trophozoites stage which was treated with a high concentration of artemisinin for 4 to 8 h, showed loss of digestive vacuoles integrity, has an ability to alkylate the protein and lipid components of digestive vacuole membrane. In the schizonts stage, there was merozoites morphology with abnormal nuclei. This condition has led to decrease *Plasmodium* parasitemia due to death or inhibition in the development stage by exposure to artemisinin antimalarial drug [16].

Conclusion

The results of this study can be concluded that artemisinin exposure with repeated passages in mice caused an increasing of ED₅₀ and ED₉₀ values. Decreasing PCT and RT and morphological changes in intraerythrocytic cycle, there was a dormant formation and loss of substance from the digestive vacuole membrane so that the crystal hemozoin is located in

the cytoplasm of the parasite and there was a formation of vacuoles.

Authors' Contributions

LM: Research project leader and coordinating research, designed study, analyzed data, drafted paper and corresponding author. TVW: Examination of PCT and RT. LRY: Processing of blood for morphological stadium observation and HP: Processing of blood for TEM. All authors read and approved the final manuscript.

Acknowledgments

The author wishes to thank Ministry of Research Technology and Higher Education (Kemenristekdikti) that has been given PUPT 2016 funding grant no 018/SP2H/LT/DRPM/III/2016/17 February 2016 for this research.

Competing Interests

The authors declare that they have no competing interest.

References

- Afonso, A., Hunt, P., Cheesman, S., Alves, A.C., Cunha, C.V., do Rosario, V. and Cravo, P. (2006) Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes *atp6* (encoding the sarcoplasmic and endoplasmic reticulum Ca^{2+} -ATPase) *tctp*, *mdr1* and *cg10*. *Antimicrob. Agents Chemother.*, 61(7): 480-489.
- Noedl, H. (2008) Evidence of artemisinin-resistant malaria in Western Cambodia. *N. Engl. J. Med.*, 359(24): 2619-2620.
- Wongsrichanalai, C. and Meshnick, S.R. (2008) Declining artesunate-mefloquine efficacy against falciparum malaria on Cambodia-Thailand border. *Emerg. Infect. Dis.*, 4(5): 716-718.
- Maslachah, L. (2013) Effect of Repeated Exposure of Artemisinin towards *Plasmodium falciparum* Resistance Development *in vitro*. Dissertation Airlangga University.
- Craig, A.G., Grau, C.G., Janse, C., James, W., Kazura, J.W., Milner, D., Barnwell, J.W., Turner, G. and Langhorne, J. (2012) The role of animal models for research on severe malaria. *PLoS Pathog.*, 8(2): e1002401.
- Muregi, F.W., Ohta, I., Masato, U., Kino, H. and Ishih, A. (2011) Resistance of a rodent malaria parasite to a thymidylate synthase inhibitor induces an apoptotic parasite death and imposes a huge coat of fitness. *Plos One*, 6(6): e21251.
- Kiboi, D.M., Irungu, B.N., Langat, B., Wittlin, S., Brun, R., Chollet, J., Abiodun, O. and Nganga, J.K. (2009) *Plasmodium berghei* ANKA: Selection of resistance to piperazine and lumefantrine in a mouse model. *Exp. Parasitol.*, 122: 196-202.
- Henriques, G., Martinelli, A., Rodrigues, L., Modrzyńska, K., Fawcett, R. and Houston, D.R. (2013) Artemisinin resistance in rodent malaria - Mutation in the AP2 adaptor M-chain suggest involvement of endocytosis and membrane protein trafficking. *Malar. J.*, 12: 118.
- Garcia, C.R., de Azevedo, M.F., Wunderlich, G., Budu, A., Young, J.A. and Bannister, L. (2007) *Plasmodium* in the post genomic era: New insight into molecular cell biology of malaria parasites. *Int. Rev. Cell Mol. Biol.*, 266: 85-156.
- Moll, K., Kaneko, K., Scherf, A. and Wahlgren, M. (2013) *Methods in Malaria Research*. 6th ed. MR4/ATCC, UK. p1-464.
- Kimani, S.K., Ng'ang'a, J.K., Kariuki, D.W., Kinjua, J. and Kiboi, D.M. (2014) *Plasmodium berghei* ANKA: Selection of pyronaridine resistance in mouse model. *Afr. J. Biochem. Res.*, 12: 111-117.
- La Crue, A.N., Scheel, M., Kennedy, K., Kumar, N. and Kyle, D.E. (2011) Effects of artesunate on parasite recrudescence and dormancy in rodent malaria model *Plasmodium vinckei*. *Plos One*, 6(10): e26689.
- Sanz, L.M., Crespo, B., De-Cozar, C., Ding, X.C., Liengo, J.L., Burrows, J.N., Garcia-Butos, J.F. and Gambo, F.J. (2012) *P. falciparum in vitro* killing rates allow to discriminate between different antimalarial mode of action. *Plos One*, 7(2): e30949.
- Veiga, M.I., Ferreira, P.E., Schmidt, B.A., Schmidt, B.A., Ribacke, U., Bjorkman, A., Tichopad, A. and Gil, J.P. (2010) Antimalarial exposure delays *Plasmodium falciparum* intraerythrocytic cycle and drives drug transporter genes expression. *Plos One*, 5(8): e12408.
- Crespo, M.P., Avery, T.D., Hanssen, E., Fox, E., Robinson, T.V., Valente, P. and Tilley, L.T. (2008) Artemisinin And series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology. *Antimicrob. Agents Chemother.*, 52(1): 98-109.
- Beez, D., Sanchez, C.P., Stein, W.D. and Lanzer, M. (2010) Genetic predisposition favors the acquisition of stable artemisinin resistance in malaria parasites. *Antimicrob. Agents Chemother.*, 55(1): 50-55.
- Cheng, Q., Kyle, D.E. and Gatton, M.L. (2012) Artemisinin resistance in *Plasmodium falciparum*: A process linked to dormancy. *Int. J. Parasitol.*, 2: 249-255.
- Maslachah, L. (2015) Phenotypic profile of *Plasmodium falciparum* papua 2300 strain *in vitro* exposed with antimalarial artemisinin. *MKB*, 47(3): 129-136.
- Witkowski, B., Lelievre, J., Barragan, M.J.L., Laurent, V., Su, X., Berry, A. and Vical, F.B. (2010) Increased tolerance to artemisinin in *Plasmodium falciparum* is mediated by a quiescence mechanism. *Antimicrob. Agents Chemother.*, 54(5): 1872-1877.
- Tucker, M.S., Mutka, T., Sparks, K., Patel, J. and Kyle, D.E. (2012) Phenotypic and genotypic analysis of *in vitro* selected artemisinin resistant progeny of *Plasmodium falciparum*. *Antimicrob. Agents Chemother.*, 56(1): 302-314.
- Chavchich, M., Gerena, L., Peters, J., Chen, N., Cheng, Q. and Kyle, D.E. (2010) Role of *pfmdr1* amplification and expression in induction of resistance to artemisinin derivatives in *Plasmodium falciparum*. *Antimicrob. Agents Chemother.*, 54: 2455-2464.
- Teuscher, F., Chen, N., Kyle, D.E., Gatton, M.L. and Cheng, Q. (2012) Phenotypic changes in artemisinin resistant *Plasmodium falciparum* line *in vitro*: Evidence for decreased sensitivity to dormancy and growth inhibition. *Antimicrob. Agents Chemother.*, 56(1): 428-431.
- Teuscher, F., Gatton, M.L., Chen, N., Peters, J., Kyle, D.E. and Cheng, Q. (2010) Artemisinin induced dormancy in *Plasmodium falciparum*; duration, recovery rates, and implications in treatment failure. *J. Infect. Dis.*, 202(9): 1362-1368.
